"SAGA Diagnostics...redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five posters—three new studies and two trials in progress—at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9-12, 2025 in San Antonio, TX."
"SAGA Diagnostics AB...has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca...SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies."
"SAGA Diagnostics AB...adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society of Human Genetics (ASHG) on October 14."